COMPOUND OVERVIEW

Sermorelin (GHRH 1-29 NH2) is a synthetic 29-amino acid peptide corresponding to the N-terminal active fragment of endogenous growth hormone-releasing hormone (GHRH). It is the smallest GHRH fragment known to retain full biological activity at the GHRH receptor. Sermorelin stimulates the pituitary gland to produce and secrete endogenous growth hormone in a physiologically pulsatile manner — preserving natural GH regulation mechanisms and the hypothalamic-pituitary feedback loop. It is one of the most extensively studied GHRH analogues and serves as a foundational research tool in GH axis pharmacology, anti-aging biology, and metabolic research.

MECHANISM OF ACTION

Sermorelin binds to GHRH receptors (GHRHR) on anterior pituitary somatotrophs with high affinity, triggering intracellular cAMP production and subsequent GH synthesis and secretion. Its action is physiologically regulated — somatostatin (SRIH) can counter its effects, preserving the natural oscillatory pattern of GH secretion. This contrasts with direct GH administration, which bypasses regulatory feedback. Sermorelin’s shorter sequence (29 vs. 44 amino acids) retains full receptor binding capability while offering a simpler synthetic profile. Research has demonstrated that Sermorelin can restore age-related declines in GH pulse amplitude and IGF-1 levels in aged research models.

RESEARCH APPLICATIONS

• GH axis stimulation and GHRH receptor pharmacology research
• Pulsatile GH secretion pattern studies
• IGF-1 regulation and downstream anabolic pathway research
• Age-related GH decline and restoration research models
• Body composition and metabolic research protocols
• Sleep architecture and nocturnal GH secretion studies
• Baseline GHRH activity comparison studies vs. longer GHRH analogues

KEY RESEARCH FINDINGS

• Research demonstrates Sermorelin significantly increases GH pulse amplitude in aged animal models toward levels seen in young counterparts
• IGF-1 restoration studies confirm dose-dependent elevation with sustained Sermorelin research protocols
• Body composition research shows favorable shifts in lean mass and adipose tissue with extended Sermorelin administration
• Sleep study research correlates Sermorelin-induced GH pulses with slow-wave sleep architecture
• Receptor binding studies confirm Sermorelin’s full agonism at GHRHR with Ki values comparable to full-length GHRH
• Comparative studies between Sermorelin and CJC-1295 elucidate duration and amplitude differences in GH secretion patterns

STORAGE & HANDLING

• Store lyophilized at -20°C; stable up to 24 months
• Reconstitute with bacteriostatic water; store at 2–8°C; use within 28 days
• Protect from heat and UV light
• Do not freeze reconstituted solution
• Handle with sterile research technique

SPECIFICATIONS

DISCLAIMER: This compound is sold strictly for laboratory and research purposes only. It is not intended for human consumption, clinical use, or veterinary application. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. For use by licensed researchers and qualified professionals only. You must be 21 years of age or older to purchase.

usaminopeptides.com · For Researcher Inquiries Contact: info@usaminopeptides.com